Attovia is a pre-revenue biotech where insiders bought $68.4M (9.247% of market cap) while the shares sit in capitulation-style selling, 42% off their high, with quality below the engine's floor.
Thesis pillars
- Heavy Insider Buying↑Improving
- Capitulation Momentum→Stable
- Pre Revenue Cash Burn↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Oct 11, 2026
Attovia Therapeutics, Inc. (ATTO) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $15.27: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 9.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products... Read more
Sell if holding. Engine safety override at $15.27: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 9.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 3d<=7d. Suitability: speculative.
Recent developments
updated Nov 5, 2026Recent Developments — Attovia Therapeutics, Inc.
Latest news
- NEWS Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 — fiscal.ai Nov 5, 2026 positive
- NEWS Attovia Says Phase 1b ATTO-1310 Gave 82% Of Chronic Itch Patients 4-Point Relief At Week 12 vs. 22% On Placebo; Atopic D — benzinga Nov 5, 2026 positive
- NEWS Attovia Therapeutics to Participate in Upcoming Investor Conferences — fiscal.ai Oct 27, 2026 neutral
- NEWS Attovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress A — benzinga Sep 28, 2026 positive
- NEWS Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday — benzinga Sep 4, 2026 positive
Latest item Nov 5, 2026 · Generated 2026-11-08T11:42:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.27: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 9.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $14.20. Score 5.9/10, moderate confidence.
Analyst target: $36.71 (+140.4% upside). Prior stop was $14.20. Stop-loss: $14.20.
Quality below floor (3.0 < 4.0); Value-trap signals (2/5): Margin compression (op margin -39.6%), Material insider selling (21 sells, 1.01% of cap).
Attovia Therapeutics, Inc. trades at a P/E of N/A (forward -6.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
11 analysts rate ATTO, with a consensus score of 4.3/5. 5 analysts publish price targets averaging $42.
What does Attovia Therapeutics, Inc. do?Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated...
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.